Difference between revisions of "Multiple myeloma - historical"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "back to top" to "back to top")
m (Text replacement - "<span style="background:#00CD00; padding:3px 6px 3px 6px; border-color:black; border-width:2px; border-style:solid;">Phase III</span>" to "style="background-color:#00CD00"|Phase III")
Line 25: Line 25:
 
|-
 
|-
 
|[http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.1997.d01-2122.x/abstract Raje et al. 1997]
 
|[http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.1997.d01-2122.x/abstract Raje et al. 1997]
−
|<span
+
|style="background-color:#00CD00"|Phase III
−
style="background:#00CD00;
 
−
padding:3px 6px 3px 6px;
 
−
border-color:black;
 
−
border-width:2px;
 
−
border-style:solid;">Phase III</span>
 
 
|[[#VAMP|VAMP]]
 
|[[#VAMP|VAMP]]
 
|-
 
|-
Line 56: Line 51:
 
|-
 
|-
 
|[http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.1997.d01-2122.x/abstract Raje et al. 1997]
 
|[http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.1997.d01-2122.x/abstract Raje et al. 1997]
−
|<span
+
|style="background-color:#00CD00"|Phase III
−
style="background:#00CD00;
 
−
padding:3px 6px 3px 6px;
 
−
border-color:black;
 
−
border-width:2px;
 
−
border-style:solid;">Phase III</span>
 
 
|[[#C-VAMP|C-VAMP]]
 
|[[#C-VAMP|C-VAMP]]
 
|-
 
|-
Line 86: Line 76:
 
|-
 
|-
 
|[http://jco.ascopubs.org/content/24/6/929.full Barlogie et al. 2006 (SWOG S9321)]
 
|[http://jco.ascopubs.org/content/24/6/929.full Barlogie et al. 2006 (SWOG S9321)]
−
|<span
+
|style="background-color:#00CD00"|Phase III
−
style="background:#00CD00;
 
−
padding:3px 6px 3px 6px;
 
−
border-color:black;
 
−
border-width:2px;
 
−
border-style:solid;">Phase III</span>
 
 
|[[#Melphalan_.26_TBI_-.3E_autologous_hematopoietic_cell_transplant|Melphalan & TBI -> autoHCT]]
 
|[[#Melphalan_.26_TBI_-.3E_autologous_hematopoietic_cell_transplant|Melphalan & TBI -> autoHCT]]
 
|-
 
|-

Revision as of 06:25, 25 October 2016

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Please go to the multiple myeloma regimen page to find other regimens.

49 regimens on this page
88 variants on this page


Untreated

C-VAMP

back to top

C-VAMP: Cyclophosphamide, Vincristine, Adriamycin (Doxorubicin), MethylPrednisolone

Regimen

Study Evidence Comparator
Raje et al. 1997 Phase III VAMP

References

  1. Raje N, Powles R, Kulkarni S, Milan S, Middleton G, Singhal S, Mehta J, Millar B, Viner C, Raymond J, Treleaven J, Cunningham D, Gore M. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. Br J Haematol. 1997 Apr;97(1):153-60. link to original article PubMed

VAMP

back to top

VAMP: Vincristine, Adriamycin (Doxorubicin), MethylPrednisolone

Regimen

Study Evidence Comparator
Raje et al. 1997 Phase III C-VAMP

References

  1. Raje N, Powles R, Kulkarni S, Milan S, Middleton G, Singhal S, Mehta J, Millar B, Viner C, Raymond J, Treleaven J, Cunningham D, Gore M. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. Br J Haematol. 1997 Apr;97(1):153-60. link to original article PubMed

VBMCP

back to top

VBMCP: Vincristine, BiCNU (Carmustine), Melphalan, Cyclophosphamide, Prednisone

Regimen

Study Evidence Comparator
Barlogie et al. 2006 (SWOG S9321) Phase III Melphalan & TBI -> autoHCT

References

  1. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF Jr, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006 Feb 20;24(6):929-36. Epub 2006 Jan 23. Erratum in: J Clin Oncol. 2006 Jun 10;24(17):2687. Moore, Dennis F Jr [added]. link to original article PubMed
    1. Update: Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol. 2010 Mar 1;28(7):1209-14. Epub 2010 Jan 19. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543. link to original article PubMed

Consolidation after upfront therapy

Melphalan & TBI -> autologous hematopoietic cell transplant

back to top

Regimen

Study Evidence Comparator Efficacy
Attal et al. 1996 (IFM90) Phase III VMCP/BVAP x 18 Seems to have superior OS
Moreau et al. 2002 (IFM 9502) Phase III High-dose melphalan & autologous transplant Might have inferior OS
Attal et al. 2003 (IFM94) Phase III Tandem (melphalan -> autoHCT, then melphalan & TBI -> autoHCT)
Barlogie et al. 2006 (SWOG S9321) Phase III VBMCP

Treatment in IFM90 was preceded by 4 to 6 alternating cycles of VMCP and BVAP. Treatment in IFM 9502 and SWOG S9321 was preceded by VAD x 3.

  • Melphalan (Alkeran) 140 mg/m2 IV (day not specified)
  • Total-body irradiation in 2 Gy fractions once per day x 4 = total dose of 8 Gy, without lung shielding

One course; relative date of stem cell re-infusion not specified

Followed by interferon alfa maintenance.

References

  1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996 Jul 11;335(2):91-7. link to original article contains verified protocol PubMed
    1. Update: Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol. 2010 Mar 1;28(7):1209-14. Epub 2010 Jan 19. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543. link to original article PubMed
  2. Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, Sotto JJ, Guilhot F, Marit G, Doyen C, Jaubert J, Fuzibet JG, François S, Benboubker L, Monconduit M, Voillat L, Macro M, Berthou C, Dorvaux V, Pignon B, Rio B, Matthes T, Casassus P, Caillot D, Najman N, Grosbois B, Bataille R, Harousseau JL; Intergroupe Francophone du Myélome. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood. 2002 Feb 1;99(3):731-5. link to original article PubMed
  3. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, Monconduit M, Hulin C, Caillot D, Bouabdallah R, Voillat L, Sotto JJ, Grosbois B, Bataille R; InterGroupe Francophone du Myélome. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003 Dec 25;349(26):2495-502. Erratum in: N Engl J Med. 2004 Jun17;350(25):2628. link to original article PubMed
    1. Update: Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol. 2010 Mar 1;28(7):1209-14. Epub 2010 Jan 19. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543. link to original article PubMed
  4. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF Jr, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006 Feb 20;24(6):929-36. Epub 2006 Jan 23. Erratum in: J Clin Oncol. 2006 Jun 10;24(17):2687. Moore, Dennis F Jr [added]. link to original article refers to protocol in Barlogie et al. 1984 PubMed
    1. Update: Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol. 2010 Mar 1;28(7):1209-14. Epub 2010 Jan 19. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543. link to original article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Multiple_myeloma_-_historical&oldid=12231"